FDA Approves Meloxicam and Rizatriptan (Symbravo) for Acute Migraine With or Without Aura
Axsome Therapeutics announced that the FDA approved the NDA for AXS-07 to treat acute migraine with or without aura on January 30, 2025.
Axsome Therapeutics announced that the FDA approved the NDA for AXS-07 to treat acute migraine with or without aura on January 30, 2025.
Two patients with congenital generalized lipodystrophy type 1 due to a variant in AGPAT2 (c.589-2A→G) who had been receiving insulin and metreleptin were switched to…
Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the…
The new technique could produce materials for use in helicopters, airplanes and spacecraft.
Power demand from data centers is soaring as artificial intelligence grows more advanced. Here’s how to make sense of it all.
Operator, a new computer-using tool from OpenAI, is brittle and occasionally erratic, but it points to a future of powerful A.I. agents.
A letter submitted to the U.S. Senate that states it was sent by physicians in support of Robert F. Kennedy Jr.’s nomination as secretary of…
Do you have an experience navigating prior authorization to get medical treatment that you’d like to share with us for our reporting?
Test results on the sick people are pending, and a top WHO official said the outbreak response is proceeding rapidly.
My HealthNewsReview.org website, which published daily for 16 years, is now gone. But this Substack will weigh in on health care news, especially when I…
Test results on the sick people are pending, and a top WHO official said the outbreak response is proceeding rapidly.